Canada’s Drug Agency Issues Final Positive Recommendation Supporting Public Reimbursement Of LEQEMBI® (Lecanemab) For Early Alzheimer’s Disease

Canada’s drug regulatory agency has issued a final positive recommendation supporting the public reimbursement of Leqembi (lecanemab) for patients with early Alzheimer’s disease. This marks a significant step toward expanding access to the drug, which has shown promise in slowing disease progression. The decision is expected to influence policy and funding decisions across the country, potentially making Leqembi more accessible to Canadian patients.

The Canadian Agency for Drugs and Technologies in Health (CADTH) announced on March 2026 that it has completed its review and recommended the public reimbursement of Leqembi, a drug developed by Eisai and Biogen. The recommendation follows a thorough assessment of clinical data, safety profiles, and cost-effectiveness analyses. The agency’s final report supports the drug’s use specifically for early-stage Alzheimer’s patients, a group at high risk of rapid cognitive decline.

Leqembi, which received approval from Health Canada earlier this year, is an antibody therapy designed to target amyloid plaques in the brain, a hallmark of Alzheimer’s disease. The recommendation indicates that the drug’s benefits in slowing disease progression outweigh potential risks, and that its inclusion in public drug plans is justified based on current evidence. The decision now moves to the federal and provincial governments for final funding approval, which could see Leqembi become available through publicly funded health services.

Officials from CADTH emphasized that the recommendation is based on rigorous review processes, and that it aims to improve treatment options for a growing patient population. The move aligns with broader international trends toward wider adoption of disease-modifying therapies for Alzheimer’s, although Canada’s decision marks a notable policy shift given ongoing debates about drug costs and equitable access.

Implications of the Reimbursement Recommendation for Alzheimer’s Care in Canada

This positive recommendation could significantly improve access to Leqembi for Canadian patients with early Alzheimer’s, potentially transforming treatment options and disease management. By supporting public reimbursement, Canada may reduce financial barriers, allowing more patients to benefit from a therapy that has demonstrated the ability to slow cognitive decline. This decision also signals a shift toward embracing newer, disease-modifying treatments within the public health system, which could influence future drug policy and funding decisions.

Healthcare providers and patient advocacy groups have welcomed the move, viewing it as a step toward more comprehensive Alzheimer’s care. However, some experts caution that the real-world impact will depend on final funding allocations and the logistics of drug delivery, including monitoring and managing side effects. Overall, the decision underscores the importance of integrating innovative therapies into publicly funded health systems amid rising Alzheimer’s prevalence.

Background on Canada’s Alzheimer’s Treatment Policies

Alzheimer’s disease remains a major public health challenge in Canada, with an aging population driving increased demand for effective treatments. Historically, access to disease-modifying therapies has been limited by high costs and regulatory hurdles. Canada’s health authorities have been cautious about adopting new Alzheimer’s drugs, often waiting for comprehensive reviews and cost-effectiveness data before supporting public funding.

Leqembi’s approval by Health Canada earlier this year marked a significant milestone, as it was among the first therapies targeting amyloid pathology with demonstrated slowing of cognitive decline. The recent recommendation by CADTH builds on this development, reflecting a broader shift toward integrating innovative Alzheimer’s treatments into Canada’s healthcare system.

Globally, several countries are evaluating or have already adopted similar policies to include Leqembi in publicly funded programs, amid ongoing debates about its long-term benefits and cost. The Canadian decision aligns with this international trend, though it is still subject to final government approvals and budget considerations.

Remaining Questions About Implementation and Funding

While the recommendation is confirmed, details about the final funding process, coverage scope, and patient eligibility criteria remain unclear. It is not yet confirmed when Leqembi will be available through public plans, nor how provinces will coordinate distribution and monitoring. Additionally, questions about long-term cost-effectiveness and real-world safety continue to be discussed among experts.

Next Steps for Policy and Access in Canada

The final step involves government approval of funding and inclusion in provincial drug formularies. This process will determine the timeline for broad public access. Healthcare providers and patient groups will likely be involved in developing guidelines for use, monitoring, and managing side effects. Expect further announcements from health authorities in the coming months outlining the implementation plan and eligibility criteria.

Key Questions

When will Leqembi be available through Canada’s public health system?

The exact timeline depends on government approval of funding, which is expected to follow the recommendation. No specific date has been announced yet.

Will all provinces cover Leqembi once approved?

Coverage decisions are made at the provincial level. While the federal recommendation supports public reimbursement, each province will determine its own coverage policies.

Are there concerns about the safety of Leqembi?

Safety profiles are under ongoing review. While clinical trials showed manageable side effects, long-term safety data are still being collected, and proper monitoring will be essential.

How much will the drug cost once publicly funded?

The final cost to the public system has not been disclosed. The recommendation is based on cost-effectiveness analyses, but actual prices will depend on negotiations and final agreements.

Source: primary